evid momentum
momentum evid guidanc look risk-
adjust shift dash could prove conserv
backhalf given expans pay go model
improv ex us underli growth horizon ap roll-out
could come remain underappreci
beat expect deliv sale vs mse beat
driven us us omnipod deliv sale vs mse
beat us beat driven robust new patient growth highest add
ever driven medicar medicaid expans on-going
shift pharmaci channel coverag grew live ex us
deliv sale beat vs mse busi
continu grow line guidanc high-teen underli
growth drug deliveri deliv vs mse beat
guidanc encourag back-half insulet first quarter strong
start year busi saw broad beat across divis rais
guidanc suggest improv remaind year
multipl opportun outperform risk-adjust guidanc includ
acceler shift dash pharmaci dme greater visibl
underli ex us growth
us guidanc optic seem weaker rel
strength may toughest quarter dash impact
shift pharmaci see preview yet underli basi
suggest bp momentum deceler manag
rais us guidanc rais
midpoint beat guidanc appropri set given
dash/pharmaci transit see upsid estim driven
broad momentum seen new patient add medicar
medicaid increas see
ex us guidanc encourag expect
rais estim midpoint guidanc
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
guidanc essenti unchang midpoint roughli in-lin
beat underli growth remain in-lin high-teen
rang manag highlight call
discuss new cfo wayd mcmillan leav us encourag
prospect backhalf year underli growth remain
robust see greater visibl catalyst greater comfort
ex us outlook
path horizon ap firm call event number
meaning pipelin updat horizon ap pivot begin later year
manag highlight possibl trial serv soft roll-out
set stage broad commerci roll-out ahead
expect horizon function competit
better form factor set stage competit integr offer
pharmaci see highli differenti offer vs peer ultim
leav us encourag prospect submiss expect
come week expect approv earli timelin
provid see possibl
path sale manag remain enthusiast long-
term growth opportun busi reiter confid
deliv sale continu see path target
horizon ap remain catalyst account model
onu omnipod growth go forward assum declin
drug deliveri impli y/i omnipod growth impli step
high end guidanc underli us growth
us high-teen low growth ex us manag believ
driver hand deliv target medicare/medicaid coverag
anima direct distribut europ on-going shift pharmaci
us model risk-conserv estim
guidanc remain construct insulet abil deliv
high teen oper margin rais price target
prior base ev sale high growth smid cap peer
group
long-term omnipod growth sustain
long-term omnipod growth sustain
remain comfort near-term
revenu trend omnipod somewhat
de-risk competit ap launch given
mdi posit shift pharmaci
drive near term volatil
longer term driver growth path
revenu becom clear driven
channel shift pharmaci medicare/unh
ex us growth
us new anima patient sustain mid-teen
growth us
profit concern
price target reflect ev sale multipl
base case discount high growth smid cap
ev/sal support dcf analysi
ev/sal support dcf analysi
ypsome disrupt transient ex us reacceler
underli growth medicar shift pharmaci acceler us
growth ap competitor prove market expans immateri
omnipod growth expand larger type market
disclosur addit drug deliveri deal materi increas valu
busi greater scale oper effici pharmaci
channel drive margin opportun next year
ev/sal support dcf analysi
ev/sal support dcf analysi
ex us growth improv meaning ypsome gross up near term
disrupt fade us growth remain stabl driven
medicar shift pharmaci mdi pediatr posit
insul omnipod ap competitor risk remain path
sale pipelin product sustain growth gm clear
like floor dash roll horizon ap launch
base case reflect ev sale multipl discount
ev/sal support dcf analysi
ev/sal support dcf analysi
ypsome disrupt prove difficult manag ex us ap competit slow
pediatr mdi adopt medicar expans fail off-set
competit headwind dash adopt modest ap timelin slip u-
fail expand reach type market drug deliveri
sale declin biosimilar lead neulasta declin path profit
becom less clear greater invest requir support growth
direct distribut ex us shift
pharmaci show us path gm
medicar shift
pharmaci sustain us growth direct
path profit improv
direct distribut ex us shift
pharmaci us
dash roll provid
foundat cgm integr ap
roll-out dash
risk achiev price
market share ap competitor ii limit
convers anima patient iii
ypsome disrupt greater expect
iv dash horizon ap timelin slip
path profit becom less clear
ypsome transit ii disclosur
abil drive manufactur oper
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
y/i growth new patient add
cash equival
prepaid expens current asset
accru expens current liabil
current portion long-term debt
current portion capit leas oblig
lt debt net discount
non-cash interest expens
loss extinguish long-term debt
provis bad debt
net chang work capit
proce purchas short term invest
proce divestitur
net invest
princip payment capit leas oblig
proce issuanc common stock
payment withhold tax connect
vest restrict stock unit
proce issuanc long-term debt net
repay long-term debt
net financ
effect exchang rate chang cash
begin period
end period
